Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.

Perlis RH, Beasley CM Jr, Wines JD Jr, Tamura RN, Cusin C, Shear D, Amsterdam J, Quitkin F, Strong RE, Rosenbaum JF, Fava M.

Psychother Psychosom. 2007;76(1):40-6.

PMID:
17170562
2.

Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study.

Zisook S, Trivedi MH, Warden D, Lebowitz B, Thase ME, Stewart JW, Moutier C, Fava M, Wisniewski SR, Luther J, Rush AJ.

J Affect Disord. 2009 Sep;117(1-2):63-73. doi: 10.1016/j.jad.2009.01.002. Epub 2009 Feb 14.

PMID:
19217668
3.

Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.

Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH, Smoller JW.

Arch Gen Psychiatry. 2007 Jun;64(6):689-97.

PMID:
17548750
4.

Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.

Beasley CM Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN.

BMJ. 1991 Sep 21;303(6804):685-92. Erratum in: BMJ 1991 Oct 19;303(6808):968.

5.

Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications.

Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM Jr, Rosenbaum JF, Perlis RH.

J Clin Psychiatry. 2007 Jan;68(1):52-7.

PMID:
17284130
6.

A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.

Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.

Health Technol Assess. 2008 May;12(14):iii-iv, ix-60.

7.

Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials.

Beasley CM Jr, Ball SG, Nilsson ME, Polzer J, Tauscher-Wisniewski S, Plewes J, Acharya N.

J Clin Psychopharmacol. 2007 Dec;27(6):682-6.

PMID:
18004137
8.

Suicidal thinking and behavior during treatment with sertraline in late-life depression.

Nelson JC, Delucchi K, Schneider L.

Am J Geriatr Psychiatry. 2007 Jul;15(7):573-80.

PMID:
17586782
9.

The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.

March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J.

Arch Gen Psychiatry. 2007 Oct;64(10):1132-43. Erratum in: Arch Gen Psychiatry. 2008 Jan;65(1):101.

PMID:
17909125
10.
11.

Suicidal risk during controlled clinical investigations of fluvoxamine.

Letizia C, Kapik B, Flanders WD.

J Clin Psychiatry. 1996 Sep;57(9):415-21.

PMID:
9746450
12.

Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment.

Michelson D, Schmidt M, Lee J, Tepner R.

J Sex Marital Ther. 2001 May-Jun;27(3):289-302.

PMID:
11354934
13.

NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients.

Petersen T, Papakostas GI, Bottonari K, Iacoviello B, Alpert JE, Fava M, Nierenberg AA.

Psychiatry Res. 2002 Jan 31;109(1):9-16.

PMID:
11850046
14.

Lack of association between fluoxetine and suicidality in bulimia nervosa.

Wheadon DE, Rampey AH Jr, Thompson VL, Potvin JH, Masica DN, Beasley CM Jr.

J Clin Psychiatry. 1992 Jul;53(7):235-41.

PMID:
1639742
15.

Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder.

Tauscher-Wisniewski S, Disch D, Plewes J, Ball S, Beasley CM.

Psychol Med. 2007 Nov;37(11):1585-93. Epub 2007 Jul 20. Review.

PMID:
17640442
16.

Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression.

Tollefson GD, Rampey AH Jr, Beasley CM Jr, Enas GG, Potvin JH.

J Clin Psychopharmacol. 1994 Jun;14(3):163-9.

PMID:
8027412
17.

What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?

Demyttenaere K, Albert A, Mesters P, Dewé W, De Bruyckere K, Sangeleer M.

J Clin Psychiatry. 2005 Jul;66(7):859-63.

PMID:
16013901
18.

Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.

Krystal A, Fava M, Rubens R, Wessel T, Caron J, Wilson P, Roth T, McCall WV.

J Clin Sleep Med. 2007 Feb 15;3(1):48-55.

PMID:
17557453
19.

Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial.

Friedman ES, Wisniewski SR, Gilmer W, Nierenberg AA, Rush AJ, Fava M, Zisook S, Balasubramani GK, Trivedi MH.

Depress Anxiety. 2009;26(7):612-21. doi: 10.1002/da.20568.

PMID:
19382183
20.

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.

Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A.

Depress Anxiety. 2009;26(7):607-11. doi: 10.1002/da.20589.

PMID:
19496103

Supplemental Content

Support Center